ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2025-11-12 01:33Core Viewpoint - Zhifei Biological experienced a slight increase in stock price, with significant fluctuations in financing and margin trading activities, indicating a mixed sentiment among investors [1][2]. Financing Summary - On November 11, Zhifei Biological had a financing buy-in amount of 109 million yuan, with a net financing buy of -1.06 million yuan, reflecting a cautious approach from investors [1]. - The total financing balance reached 14.32 billion yuan, accounting for 2.75% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1]. - Margin trading showed a high level of short selling, with 6,600 shares sold and a remaining short balance of 392.47 million yuan, exceeding the 90th percentile level over the past year [1]. Company Performance Summary - As of September 30, Zhifei Biological reported a total of 131,600 shareholders, a decrease of 3.17% from the previous period, while the average circulating shares per person increased by 3.28% to 10,750 shares [2]. - For the period from January to September 2025, the company achieved a revenue of 7.627 billion yuan, a significant year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, a decline of 156.10% [2]. - Since its A-share listing, Zhifei Biological has distributed a total of 7.318 billion yuan in dividends, with 3.194 billion yuan distributed in the last three years [2]. Institutional Holdings Summary - As of September 30, 2025, the top ten circulating shareholders of Zhifei Biological included Hong Kong Central Clearing Limited as the third-largest shareholder, holding 33.5608 million shares, a decrease of 2.7888 million shares from the previous period [2]. - Other notable institutional shareholders, such as E Fund's various ETFs, also reported reductions in their holdings, indicating a trend of decreasing institutional interest [2].